U.S. Department of Health and Human Services
Kenneth Jacobson
 

 Contact Info

 
Tel: 301-496-9024
Email: kajacobs@helix.nih.gov
 

 Select Experience

 
  • Bantrel FellowWeizmann Institute of Science, Department of Organic Chemistry1983
  • Ph.D.University of California, San Diego1981
  • M.S.University of California, San Diego1978
  • B.A.Reed College1975
 

 Related Links

 
Specialties
  • Chemistry/Chemical Biology
  • Molecular Biology/Biochemistry
  • Molecular Pharmacology/Toxicology

​Resources

Patents, materials, and other research resources appear below. Some resources may be available for use through Material Transfer Agreements (MTAs) or licensing agreements.

Resource Name Description
A3 Adenosine Receptor Antagonists and Partial Agonists (U.S. Patent Application Number 13/056,997)

Disclosed are A3 adenosine receptor antagonists and/or partial agonists of formula (I): wherein R1 to R5 are as described herein, as well as pharmaceutical compositions thereof and methods of use thereof. The antagonists or partial agonists find use…

Purine Derivatives as A3 Receptor-selective Agonists (U.S. Patent Application Number 13/371,081)

Disclosed are (N)-methanocarba adenine nucleosides, e.g., of formula (I) as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined…

Method of Treating Cystic Fibrosis Using 8-Cyclopentyl-1,3-Dipropylxanthine or Xanthine Amino Congeners (U.S. Patent Number 6,083,954)

A method of treating cells having a reduced apical Cl.sup.- conductance, such as that characteristic of cystic fibrosis cells, by contacting cells having a reduced apical Cl.sup.- conductance with a therapeutically effective quantity of a compound…

Dihydropyridine-, pyridine-, Benzopyran-4-one- and Triazoloquinazoline Derivative, Their Preparation, and Their Use as Adenosine Receptor Antagonists (U.S. Patent Number 6,066,642)

The present invention provides a method of identifying CFTR-binding compounds for treating cells having a reduced apical Cl.sup.- conductance, such as cystic fibrosis cells. This identification method involves the use of polypeptide I.alpha., which…

A3 Adenosine Receptor Antagonists (U.S. Patent Number 6,376,521)

This invention relates to a method of decreasing intraocular pressure by administrating an A3 subtype adenosine receptor antagonist, a calmodulin antagonist or an antiestrogen such as tamoxifen. ​

Methods for reducing Intraocular Pressure using A3 Adenosine Receptor Antagonists (U.S. Patent Number 6,528,516)

This invention relates to a method of decreasing intraocular pressure by administrating an A3 subtype adenosine receptor antagonist, a calmodulin antagonist or an antiestrogen such as tamoxifen.​

Methanocarba cycloalkyl Nucleoside Analogues (U.S. Patent Number 7,790,735)

The present invention provides novel nucleoside and nucleotide derivatives that are useful agonist or antagonists of P1 and P2 receptors. For example, the present invention provides a compound of formula A-M, wherein A is modified adenine or uracil…

Dendrimer Conjugates of Agonists and Antagonists of the GPCR Superfamily (U.S. Patent Number 8,153,781)

Disclosed are conjugates comprising a dendrimer and a ligand, which is a functionalized congener of an agonist or antagonist of a receptor of the G-protein coupled receptor (GPCR) superfamily, for example, wherein the functionalized congener is an A1…

(N)-Methanocarba Adenosine Derivatives and Their Dendrimer Conjugates as A3 Receptor Agonists (U.S. Patent Application Number 61/313,961)

Disclosed are (N)-methanocarba adenine nucleosides, e.g., of the formula (I): as A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein A, a, R2, and R3 are as…

Adenosine receptor agonists, partial agonists, and antagonists (U.S. Patent Number 13/479,973)
NIDDK announces the availability of  a highly selective A1 adenosine receptor (AR) agonist.  This receptor is neuroprotective in ischemic and epileptic models.  The A1AR-selective full agonist MRS5474  displayed anticonvulsant activity in vivo in a…
View Additional Research Resources

Clinical Trials

Open studies conducted by NIDDK Principal Investigators appear below that are currently recruiting, not yet recruiting, or available for expanded access.

Study Title
There are no associated clinical trials.
Search for more clinical trials at ClinicalTrials.gov